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Background: We investigated plasma levels of M-CSF and conventional tumor markers (HE4 and CA 125) in epithelial
ovarian cancer patients as compared to control groups: benign ovarian tumor patients (cysts) and healthy subjects.
Methods: M-CSF levels were determined by ELISA, HE4 and CA 125 levels - by CMIA method.
Results: Our results have demonstrated significant differences in the concentration levels of M-CSF, CA 125 and HE4
between the groups of ovarian cancer patients, cysts patients and the healthy controls. In the groups tested M-CSF
demonstrated equal to or higher values than both CA 125 and HE4 in diagnostic sensitivity (SE), positive and negative
predictive values (PPV, NPV), and in the area under the ROC curve (AUC), particularly in the group with the serous epithelial
sub-type of OC. Moreover, CA 125 showed better results of the aforementioned diagnostic criteria than HE4.
The combined use of the parameters studied resulted in a further, significant increase in the value of the diagnostic
indicators and in the value of the diagnostic power (AUC), especially in the early stages of ovarian cancer.
Conclusions: These findings suggest a high usefulness of M-CSF in diagnosing the serous sub-type of epithelial ovarian
cancer and in discriminating between cancer and non-carcinoma lesions, particularly in new diagnostic panels in
combination with CA 125 and HE4 for the detection of EOC in the early stages.
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Epithelial ovarian cancer (EOC) remains the most lethal
type of all gynecological cancers despite the develop-
ment of new treatments and therapies. The malignant
tumor of the ovaries occurs at all ages with variation in
histological sub-type according to age [1,2]. Established
risk factors associated with the increasing prevalence of
OC include genetics (BRCA1- breast cancer type 1 sus-
ceptibility protein and BRCA2 - breast cancer type 2
susceptibility protein), age (primarily perimenopausal
and postmenopausal status), positive familial history
(5–10%), diet (rich in meat and saturated fats), and other
reproductive factors [1,3,4]. A lack of precise early warn-
ing signs is one of the factors that further contributes to
the fact that only 25% of ovarian tumors are identified at* Correspondence: zdb@umwb.edu.pl
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unless otherwise stated.a treatable stage I [3]. In the majority of cases OC is di-
agnosed in the late stages of the disease when patients
have metastatic disease at presentation [2]. Detection at
an early stage offers a potential reduction in mortality.
Therefore, finding markers which would identify a ma-
lignant cell transformation as early as possible is of
critical importance [5].
The established tumor markers, such as CA 125
(carbohydrate antigen 125) or human epididymis protein
4 (HE4), can be used in the diagnosis and monitoring of
epithelial ovarian cancer [6-8]. A number of researchers
and clinicians have been investigating many new diag-
nostic markers, some of which have recently shown
promise, which may be useful in the diagnosis of this
type of cancer [7,9]. Different types of substances, for ex-
ample cytokines such as macrophage-colony stimulating
factor (M-CSF), vascular endothelial growth factor (VEGF)
and interleukin 10 (IL-10) [10-13], metalloproteinases
(MMP-2, MMP-7, MMP-9) and the tissue inhibitor oftral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Characteristics of ovarian cancer patients and
control groups: benign ovarian tumor and healthy subjects
Study group Number of
patients
Epithelial ovarian cancer patients 110 (100%)
• Median age (range) 58 (46–80)
-sub-type serous epithelial 61 (55%)
• Median age (range) 58 (46–81)
-sub-type endometrioid epithelial 49 (45%)











IV (metastases) 26 (23.6%)
Menopausal status: - postmenopausal 110 (100%)
Benign ovarian tumor patients 70 (100%)
-type cystis serous 35 (50%)
-type cystis endometrioides 35 (50%)
Median age (range) 52 (48–68)
Menopausal status: - postmenopausal 70 (100%)
Healthy subjects 50 (100%)
Median age (range) 56 (48–66)
Menopausal status: - postmenopausal 50 (100%)
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markers (mesothelin, B7-H4, DcR3, spondin-2) [17,18] are
currently being investigated.
Macrophage-colony stimulating factor is one of the
cytokines called hematopoietic growth factors (HGFs).
M-CSF regulates the growth, differentiation and func-
tionality of neutrophils or macrophages. Additionally,
M-CSF has also been implicated in the pathogenesis of
cancer disease [19,20]. A number of authors focused on the
role of M-CSF and its receptor in epithelial malignancies,
including those of breast [21-23], lung [24,25], pancreatic
[26], cervical [27,28], and ovarian origin [29-31].
The aim of this study was to determine plasma levels
of macrophage-colony stimulating factor in comparison
to plasma levels of HE4 and the established CA 125
tumor marker in epithelial ovarian cancer (EOC) pa-
tients in relation to the control groups: patients with a
benign ovarian tumor and healthy subjects. Additionally,
comparisons between plasma levels of the parameters
tested and cancer stage, its histological sub-type and histo-
logical type of benign ovarian tumors were performed. Fur-
thermore, the diagnostic criteria (sensitivity, specificity,
positive and negative predictive values) and the receiver-
operating characteristic curve (ROC) for the cytokine tested
(M-CSF), HE4 and CA 125 alone and in combinations were
defined. Moreover, a correlation between the three parame-
ters studied was established.
The data obtained may be used in the evaluation of
M-CSF usefulness in diagnosing the stages and histo-
logical sub-types of ovarian cancer and in discriminating
between ovarian cancer and benign ovarian tumors, es-
pecially when analysed with HE4 and CA 125.
Methods
Patients
Table 1 shows the characteristics of patients and control
groups. The study included 110 epithelial ovarian cancer
patients (serous and endometrioid sub-types) diagnosed
by the Gynecology Group. The control groups com-
prised 70 benign ovarian tumor patients (cystis serous or
cystis endometrioides) and 50 healthy volunteers. All par-
ticipants enrolled in the study (cancer and control
groups) had postmenopausal status at the time of blood
collection. Clinical stages and histological classification
based on the criteria of the International Federation of
Gynecology and Obstetrics (FIGO) were established in
all cases. The ovarian cancer patients and the control
group (benign lesions) were treated in the Department
of Gynecology, Białystok Medical University Teaching
Hospital, Poland, between 2006–2012. Epithelial ovarian
cancer and benign ovarian tumor histopathology was
established in all cases. Patients with renal failure were
excluded from the study due to significantly elevated
HE4 concentration levels, indistinguishable from ovariancancer. Written consent including participants’ own
statements regarding their medical history (i.e. data re-
lated to reproductive history, personal or family history
of cancer, general health issues - hospitalization or sur-
gery, use of medication) and lifestyle habits including
smoking was obtained from all the subjects.
None of the patients had received chemo- or radiother-
apy before blood sample collection. Pretreatment staging
procedures included physical and blood examinations,
ultrasound scanning and chest X-rays. In addition, CT
(computed tomography) scans or MRI (magnetic resonance
imaging) were performed where necessary.
Healthy patients were recruited from apparently healthy
female employees of Białystok Medical University Teaching
Hospital between 2006 and 2012. They were not referred
from other medical centers. All subjects had undergone
annual check-ups (laboratory tests, chest x-ray, cervical cy-
tology screening, mammography). Subjects with a clinical
history of prior endometriosis or mild gynecological condi-
tions were excluded. Women included in the control group
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gynecological conditions and displayed no visible or
perceptible changes in the adnexa. The group were
examined by a gynecologist prior to blood collection
and an ultrasound examination was performed in
every case.
The study was approved by the local Ethics Committee
of the Medical University in Białystok, numbers: R-I-
002/314/2009 and R-I-002/262/2010 and all the patients
gave their informed consent for the participation in the
study.
Biochemical analyses
Venous blood samples were collected from every patient.
Blood was collected into a heparin sodium tube, centri-
fuged 1000 rpm for 15 min. to obtain plasma samples,
and stored at-850 C until assayed. M-CSF was measured
with the enzyme-linked immunosorbent assay (ELISA)
(Quantikine Human HGFs Immunoassay; R & D systems,
Abingdon, United Kingdom), according to the manufac-
turer’s protocols. Duplicate samples were assessed for each
patient. The intra-assay coefficient of variation (CV%) of
M-CSF - 3.4% at a mean concentration of 227 pg/ml,
SD = 7.7. The inter-assay coefficient of variation
(CV%) of M-CSF - 3.1% at a mean concentration of
232 pg/ml, SD = 7.3. The assay showed no significant
cross-reactivity or interference with numerous human
cytokines and other growth factors.
Plasma concentrations of HE4 and CA 125 were mea-
sured by chemiluminescent microparticle immunoassay
(CMIA) (Abbott, Chicago, IL, USA). The intra-assay CV
for HE4 - 3.7% at a mean concentration of 39.0 pmol/L,
SD = 1.4. The inter-assay CV for HE4-2.8% at a mean
concentration of 39.0 pmol/L, SD = 1.1. The intra-assay
CV for CA 125 is reported to be 2.4% at a mean concen-
tration of 43.5 U/ml, SD = 1.1. The inter-assay CV for
CA 125 is reported to be 3.9% at a mean concentration
of 43.5 U/ml, SD = 1.7.
Statistical analysis
The statistical analysis was performed using the STATIS-
TICA 8.0 PL program. A preliminary statistical analysis
(Chi-square test) revealed that the distribution of cyto-
kine and tumor marker levels did not follow normal dis-
tribution. Consequently, nonparametric methods were
used to compare levels of the parameters tested between
the groups of patients. Comparisons between two groups
were performed using the Mann–Whitney test, between
multiple groups Kruskal-Wallis tests were calculated
with post hoc comparisons according to Dwass-Steele-
Critchlow-Fligner method. The ROC analyses were uti-
lized in the evaluation of the diagnostic power of tumor
markers and the construction of the curves was per-
formed using GraphRoc Program for Windows. Markerswere compared by assessing the significance of differ-
ences between the areas under their corresponding ROC
curves. The cut-off points of M-CSF (575.80 pg/ml),
HE4 (75.90 pmol/L) and CA 125 (28.40 U/ml) were cal-
culated as 95th percentile from the control group of
healthy blood donors.
Data were presented as median and range. Statistically
significant differences were defined as comparisons result-
ing in p < 0.05. The Spearman rank correlation was used in
the correlation analyses.
Results
The median of M-CSF levels, similarly to the median
levels of the comparative tumor markers HE4 and CA
125 in the total group of OC and in every stage of ad-
vancement (I-IV) of cancer disease were significantly
higher when compared to the healthy controls (p < 0.001
in all cases) (Table 2). Moreover, plasma concentrations
of all tested parameters were significantly higher in more
advanced stages (III-IV) than those found in the early
stages (I-II) - p < 0.001 in all cases.
Patients with ovarian cancer (total group) had statisti-
cally considerably higher median levels of the parameters
researched (p < 0.001 in all cases) than those observed in
the group with benign ovarian tumors (Table 2). We also
noticed significantly higher concentrations of M-CSF in
II-IV (II - p = 0.045; III-IV - p < 0.001), of HE4 in I-IV
(I - p = 0.018; II - p = 0.001; III-IV - p < 0.001) and of CA
125 in stages II-IV (II - p = 0.034; III-IV - p < 0.001) of
EOC than in the control group with nonmalignant le-
sions of the ovary.
In the case of the total group with benign ovarian tumors,
the concentrations of M-CSF and CA 125 were significantly
different than in healthy subjects (p < 0.001).
The analysis according to the histopathological sub-
types of EOC revealed statistical differences in the
concentrations of M-CSF, HE4 and CA 125 between
every cancer sub-type group (serous and endometrioid)
and benign tumors control group (p < 0.001 in all
cases). It was also observed that the distribution of all
the tested parameters among two histological sub-
types of epithelial ovarian cancer were significantly
different (p = 0.012; p = 0.014; p < 0.001; respectively)
(Table 2).
Plasma levels of M-CSF and CA 125 in the groups
with cystis endometrioides and cystis serous were higher
than those in healthy women (in all cases p < 0.001).
Interestingly, the plasma level of HE4 was significantly
lower in patients with cystis endometrioides in com-
parison to the healthy controls (p = 0.042). In addition,
we noticed significant differences in the median HE4
(p = 0.046) and CA 125 levels (p = 0.039) when com-
paring the cystis endometrioides to the cystis serous
group (Table 2).
Table 2 Plasma levels of M-CSF, CA 125 and HE4 in tested groups
Groups
M-CSF HE4 CA 125
(pg/ml) (pmol/L) (U/ml)














































1statistically significant when comparing EOC patients with healthy subjects.
2statistically significant when comparing EOC patients with benign ovarian tumor total group.
3statistically significant when comparing patients with benign ovarian tumor and healthy subjects.
4statistically significant when comparing EOC patients in stage III or IV with stage I or II.
5statistically significant when comparing EOC patients i.e. sub-type serous with sub-type endometrioid.
6statistically significant when comparing with benign ovarian tumor group i.e. type cystis endometrioides.
7statistically significant when comparing with benign ovarian tumor group i.e. type cystis serous.
8statistically significant when comparing patients with benign ovarian tumor i.e. type cystis endometrioides with type cystis serous.
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lysis of dependence between the investigated parameters
(Additional file 1: the Spearman’s rank correlation–re-
sults, data not shown). Our analysis revealed positive
correlations between the HE4 and CA 125 concentra-
tions in the total group of EOC (R = 0.47, p < 0.001), be-
tween the M-CSF and CA 125 (R = 0.4, p = 0.046) inpatients with stage II cancer as well as between the HE4
and CA 125 levels according to the histopathological
sub-types of EOC: endometrioid (R = 0.31, p = 0.037) or
serous (R = 0.35, p = 0.008). Moreover, positive correla-
tions were also observed between the M-CSF and CA
125 levels in the healthy control group (R = 0.32, p =
0.026). The single negative correlation was obtained for
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in patients with stage II EOC.
Table 3 shows the diagnostic criteria of parameters
tested: sensitivity (SE), specificity (SP), positive predictive
value (PPV) or negative predictive value (NPV) in the
EOC patients. In the total group of EOC patients M-
CSF presented the highest diagnostic sensitivity (70%).
HE4 had the highest diagnostic SE in stage I of the
disease from among all the parameters tested, although
M-CSF demonstrated better results in stages II-IV. We
also observed a further increase in the SE value in more
advanced cancer stages (with the exception of HE4 in
stage II). The combined use of the parameters tested re-
sulted in a dramatic increase in the diagnostic SE for the
combination of HE4 +CA 125 in stage I and II, M-CSF +
CA 125 in stage III and of M-CSF +HE4 in stage IV of the
disease. The maximum range of SE was obtained for the





M-CSF HE4 CA 125 M-CS
stage I
SE 40 46 40 64
SP 94 94 92 90
PPV 87 88 87 86
NPV 61 63 61 71
stage II
SE 68 29 63 80
SP 94 94 92 90
PPV 92 83 89 89
NPV 75 57 72 82
stage III
SE 84 66 80 92
SP 94 94 92 90
PPV 93 92 91 90
NPV 85 73 82 92
stage IV
SE 88 81 84 100
SP 94 94 92 90
PPV 93 93 91 91
NPV 87 84 85 100
Total group
SE 70 55 66 84
SP 94 94 92 90
PPV 81 90 79 89
NPV 76 68 73 85
Serous epithelial
SE 74 70 64 92
SP 94 94 92 90
PPV 92 92 89 90
NPV 78 77 73 92
Endometrioid epithelial
SE 65 37 71 82
SP 94 94 92 90
PPV 91 86 90 89
NPV 73 59 81 83stage II- 92%, stage III- 96%, IV - 100% and in the total
group of OC - 86%.
In regard to the histopathological sub-types of EOC,
we demonstrated the highest range of diagnostic SE for
M-CSF in the serous epithelial group and for CA 125 in
the endometrioid epithelial group. Similarly, we observed
an increase in the SE value in during the combined ana-
lysis of two and three parameters for both sub-types of
EOC.
M-CSF and HE4 presented the highest diagnostic spe-
cificity values (94%) in every cancer group compared
and in every histopathological sub-type of EOC. The
combined use of the parameters studied resulted in a de-
crease in the diagnostic SP (Table 3).
In the total group of EOC patients the PPV had the
highest values for HE4 (90%). HE4 reached the highest
values of PPV in stage I in contrast to M-CSF, which
reached the highest values in stages II-IV. Similarly, thewith HE4 and CA 125 in epithelial ovarian cancer patients
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in the PPV values (Table 3). Additionally, we observed the
highest PPV value for M-CSF and HE4 in the serous and
for M-CSF in the endometrioid sub-types of EOC.
The negative predictive value in the total group of
ovarian cancer reached the highest values for M-CSF
(76%). M-CSF also obtained the highest value in stages
II-IV with the exception of stage I, where HE4 consist-
ently achieved the best results. Additionally, the NPV
values showed a further increase during the combined
analysis of the parameters tested (Table 3). The max-
imum value of NPV was obtained for M-CSF +HE4 and
for M-CSF +HE4+ CA 125 in stage IV of the disease al-
though very high values were also observed for the combin-
ation of two (69–94%) and three (74–94%) biomarkers
together in stages I-III of EOC. M-CSF had the highest
values in the group with serous and CA 125 in the group
with endometrioid sub-types of OC (Table 3).
The relationship between the diagnostic sensitivity and
specificity was illustrated by the ROC curve. Table 4
shows the results of our in-depth analysis of the AUC
(area under the ROC curve) of every biomarker, alone
and in combination, for every stage and for every inves-
tigated histological sub-type of the disease. The CA 125
area (0.9277) under the ROC curve is the largest in the
total group of EOC patients and its value was marginally
higher than that of M-CSF or HE4 (Figures 1 and 2).
The AUC of CA 125 was also the largest in the group of
patients with stage IV, but interestingly the AUC of M-
CSF was the largest in the group with stages I-III of the
disease. The area under the ROC curve of all the bio-
markers tested clearly illustrates an increase in their
diagnostic power concurrent with the stage of advance-
ment of the disease (with the exception of HE4 and M-
CSF in stage IV) (Table 4). Additionally, the combination
of all the parameters resulted in an increase in the diag-
nostic power in every case to the value of: 0.9069 in
stage I, 0.9443 in stage II, 0.9714 in stage III and 0.9529
in the total group of EOC. Repeatedly, the largest area
under the ROC curve was indicated for the combination
of all the aforementioned markers in patients with stage
IV cancer. According to histopathological classification,
CA125 achieved the best result in endometrioid epithe-
lial (0.9129) and M-CSF in serous epithelial sub-types of
ovarian cancer (0.9058). The AUCs of M-CSF and the
comparative tumor markers were significantly higher
compared to AUC = 0.5 in every group of EOC studied
(in all cases p < 0.001).
Discussion
The search for an effective screening test for ovarian
cancer has been the focus of intensive research efforts.
Blood flows into and out of tumors and circulates
tumor-specific protein profiles, making serum or plasmathe ideal biological media for finding a screening bio-
marker [13]. The co-expression of M-CSF and its trans-
membrane tyrosine kinase receptor has been detected in
epithelial ovarian carcinoma and could be involved in
the autocrine growth stimulation of this type of cancer.
M-CSF, known as a colony stimulating factor 1 (CSF-1),
is also a potent chemoattractant for monocytes, which in
turn, can produce factors that stimulate proliferation
of ovarian tumor cells including interleukin-1 (IL-1),
interleukin-6 (IL-6) and tumor necrosis factor (TNF).
Clinical specimens from ovarian cancer metastases
display strong immunostaining for both CSF-1 and its
receptor in contrast to noninvasive borderline tumors
and to benign ovarian tissue [27,29]. HE4 is a novel
protein and one of the more promising biomarkers for
improving the diagnostic performance in ovarian can-
cer detection. This is a precursor to the epididymal
secretory protein E4. It is overexpressed in ovarian
carcinomas, but there is minimal expression in normal
ovarian tissue. HE4 promotes migration and adhesion
of ovarian cancer cells. It was reported that HE4 could
be used as a biomarker for ovarian cancer with a spe-
cificity higher than that of CA 125. This protein was
particularly highly expressed in histologic subtypes of
serous or endometrioid ovarian carcinoma [6-8].
In this study we investigated the diagnostic usefulness
of M-CSF used alone and in combination with HE4 and
CA 125 in patients with EOC before surgical interven-
tion or chemo- and/or radiotherapy. Furthermore, we
estimated the diagnostic utility of these biomarkers in
correlation to the stage and histological type of ovarian
cancer.
Our results show that M-CSF as well as HE4 and CA
125 plasma levels in the total group of ovarian cancer
patients were statistically significantly higher in compari-
son to the group of healthy controls. Data regarding M-
CSF obtained in the present study are also in agreement
with our previous studies [10] and with research results
of other authors who compared ovarian cancer patients
with healthy volunteers, although there were differences
in the number and the composition of the groups tested
[32-34]. Significantly elevated levels of M-CSF have also
been found in the sera of patients with malignancies of
the reproductive organs [32,35,36], breast [37] or pan-
creatic and ampullary cancer [26]. Moreover, it was ob-
served that M-CSF concentrations were statistically
different in every group (the analysis related to the stage
of advancement of OC) compared to the healthy sub-
jects. Similar results for M-CSF were confirmed in our
previous investigations [10] and in the studies of other
authors [34], although their observations regarding the
highest concentrations of M-CSF related to the early
stages of the disease and concerned a larger number of
sub-types of EOC than our current study (serous,
Table 4 The diagnostic criteria of the ROC curve for M-CSF and in combination with HE4 and CA 125 in epithelial
ovarian cancer patients
Epithelial ovarian cancer The ROC criteria M-CSF HE4 CA 125 M-CSF+ HE4 M-CSF+ CA 125 HE4 + CA 125 M-CSF+ HE4 +
CA 125
stage I
AUC 0.7676* 0.7285* 0.7653* 0.8536* 0.8702* 0.8326* 0.9069*
SE 0.0681 0.0708 0.0416 0.0496 0.0433 0.0538 0.0353
95% C.I. 0.604-0.871 0.590-0.867 0.692-0.794 0.756-0.951 0.785-0.955 0.728-0.938 0.838-0.976
p AUC = 0.5 <0.001 0.0013 0.0005 <0.001 <0.001 <0.001 <0.001
stage II
AUC 0.8662* 0.7647* 0.8653* 0.9008* 0.9113* 0.9208* 0.9443*
SE 0.0483 0.0562 0.0389 0.0387 0.0393 0.0314 0.0265
95% C.I. 0.772-0.961 0.654-0.876 0.814-0.968 0.825-0.977 0.834-0.988 0.859-0.983 0.892-0.966
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
stage III
AUC 0.9336* 0.9257* 0.9114* 0.9624* 0.9608* 0.9764* 0.9714*
SE 0.0317 0.0291 0.0428 0.0250 0.0302 0.0302 0.0222
95% C.I. 0.871-0.996 0.869-0.984 0.828-0.995 0.913-1.011 0.902-1.020 0.903-1.020 0.928-1.015
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
stage IV
AUC 0.9096* 0.9125* 0.9474* 0.9872* 0.9665* 0.9422* 0.9894*
SE 0.0414 0.0428 0.0260 0.0086 0.0214 0.0353 0.0083
95% C.I. 0.829-0.991 0.829-0.996 0.897-0.998 0.970-1.004 0.925-1.008 0.873-1.012 0.973-1.006
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Total group
AUC 0.8562* 0.8324* 0.9277* 0.9257* 0.9271* 0.9182* 0.9529*
SE 0.0316 0.0321 0.0221 0.0212 0.0225 0.0223 0.0172
95% C.I. 0.794-0.918 0.769-0.895 0.884-0.972 0.884-0.967 0.883-0.971 0.874-0.963 0.919-0.967
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Serous epithelial
AUC 0.9058* 0.8722* 0.9046* 0.9491* 0.9558* 0.9390* 0.9659*
SE 0.0306 0.0347 0.0301 0.0199 0.0199 0.0233 0.0160
95% C.I. 0.846-0.966 0.805-0.964 0.846-0.964 0.910-0.989 0.917-0.995 0.893-0.985 0.930-0.997
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Endome-trioid epithelial
AUC 0.7983* 0.7845* 0.9129* 0.8978* 0.8926* 0.8927* 0.9374*
SE 0.0491 0.0467 0.0305 0.0331 0.0343 0.0330 0.0241
95% C.I. 0.702-0.894 0.694-0.876 0.854-0.973 0.833-0.963 0.825-0.960 0.828-0.958 0.890-0.985
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
(C.I. – confidence intervals of AUC).
*statistically significant when comparing tested parameters AUC’s with 0.5 AUC.
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that Suzuki and colleagues [38] found no significant dif-
ference in M-CSF levels between early and advanced
stages of OC, and this is in opposition to the results of
our study in which a group of postmenopausal women
was studied [10]. It should also be emphasized that M-
CSF and its receptor gene, c-fms, were expressed in
gynecological malignancies, and the co-expression of
M-CSF and c-fms might be related to progression to the
metastatic state [27] and is associated with poor progno-
sis [30,38]. Furthermore, it was observed that 56%
(14/25) of the patients with clinically evident OC and
normal levels of CA125 had elevated levels of M-CSF
[39]. Our results are consistent with the results of other
authors who observed increased levels of HE4 and CA125 in the group of ovarian cancer patients compared to
the healthy women group [8,40], although the groups
tested were far smaller (60 and 30 women respectively).
Similar results were obtained by Molina and others [41]
who observed higher concentrations of the aforemen-
tioned tumor markers in ovarian (111 patients) as well
as in other active gynecological cancers (32 patients) or
in different benign gynecological lesions (285 subjects).
Furthermore, other researchers have found circulating
concentrations of HE4 and CA 125 significantly higher
in patients with early and late stages of cancer compared
with healthy women, although there were differences
in ethnical characteristics of the population selected
[42,43]. The analysis of research results published by


















Figure 1 Diagnostic criteria of ROC curve for M-CSF, HE4 and CA 125 in total OC tested group.
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levels of both tumor markers which were clearly related
to the stage of the disease, with significantly higher con-
centration levels in the advanced stages III-IV than in
stages I-II [41,44].
In line with our previous report [10] and others publi-
cations [32,41,45] there was a difference in M-CSF con-
centrations between the EOC patients and the benign
(cysts) tumors groups. Gaducci et al. [45] discovered
that preoperative serum M-CSF levels were significantly
elevated in patients with epithelial OC when compared













100% - Specificity 
Figure 2 Diagnostic criteria of ROC curve for M-CSF, HE4 and CA 125 in comucinous and endometriotic cysts and also of fibromas,
thecoma and benign cystic teratomas were analysed).
Suzuki et al. [38] confirmed these findings, although ma-
lignant germ cell tumors of the ovary and mature cystic
teratomas were studied. Furthermore, Burke et al. [46]
revealed mRNA expression for M-CSF and its receptor
in a majority of malignant and benign ovarian biopsies
with minimal to no expression in the normal epithelium.
Takagi et al. [32] observed serum M-CSF levels in this
type of cancer significantly different from those in pa-
tients with a benign ovarian tumor (p < 0.01) and with





mbined analysis in total OC tested group.
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and patients with leiomyoma (p < 0.05). Comparable re-
sults were obtained in studies conducted on patients
with breast malignancies [37]. The findings of the
current study regarding comparative tumor markers cor-
respond to the findings reported in the existing literature
[43,47,48] and to our previous publications [10,36]. Sig-
nificantly higher serum concentrations of HE4 and CA
125 (p = 0.005, p = 0.001, p < 0.0001, p < 0.001, respect-
ively) [6,41,49,50] were found in OC patients than in
those with benign diseases, although there were differ-
ences in the menopausal status and composition of the
groups compared. In addition, HE4 showed a greater
than CA 125, satisfactory ability to distinguish ovarian
cancer from endometriosis [51].
In contrast to the results published by Suzuki et al.
[29] we observed significantly higher plasma levels of
M-CSF in patients with a benign ovarian tumor than in
healthy controls. These findings are similar to the results
obtained in our previous studies conducted on female
patients with uterine myoma [36]. Our present observa-
tions concerning both tumor markers are in agreement
with published evidence, although HE4 is reported to
be less frequently elevated than CA 125 in benign
gynecologic disorders [8,52,53]. Furthermore, patients
with serous epithelial OC displayed significantly differ-
ent concentrations of all the parameters studied than
those with endometrioid epithelial OC. We also dem-
onstrated significant differences in the concentrations
of the parameters tested in every group of OC sub-
types vs patients with cystis endometrioides and with
cystis serous. Comparable results, but only for CA 125,
were published by Nolen et al. [54], although benign
cases included a broad spectrum of non-malignant
lesions representing a variety of histological origins.
Significant differences were also observed, but only for
HE4 and CA 125, between the patients with cystis
endometrioides and cystis serous. These data are at
variance with other publications [28], and may have
been partly influenced by study participant selection,
although similar results have recently been reported
[7,41,55,56]. Unfortunately, we could not confirm our
findings regarding M-CSF in other publications, since
no reports on the subject are available.
The correlation between M-CSF, HE4 and CA 125
levels was estimated by Spearman’s rank correlation
test and most of the measured values tended to in-
crease for every marker. However, the degree of the
correlation was not particularly strong (R: 0.32–0.47),
and there were some discordant results. This suggests
that each marker was elevated concurrently or under
different conditions, and these results also support the
necessity of combining the three markers. We found
similar results in the existing literature [8,10,52].In our analysis of postmenopausal subjects, we found
that M-CSF alone provided the highest SE, PPV and
NPV, (68–88%, 91–93%, 75–87% respectively) of any in-
dividual biomarker tested (with the exception of HE4 -
stage I and CA 125 - EOC endometrioid sub-type). Our
results are in agreement with the investigation of Skates
et al. [33], whose study group comprised only 60 pa-
tients - 50% fewer than our study group, and with the
publications of other authors [57] as well as with our
previous studies [10,58]. The diagnostic SP was very
high and reached the value of 94% for M-CSF and HE4,
and 92% for CA 125 and these results are in accordance
with [36,59] or at variance with [10] our earlier papers
and the existing literature [41,52] but they may have
been partly influenced by study participant selection.
Nonetheless, a multi-marker approach appears to hold
promise for detecting early stage ovarian cancers [6].
Despite a decrease in specificity (86%) and PPV (85%),
when M-CSF was combined with conventional markers,
sensitivity levels improved to 80% - stage I, to 92–100%
in stages II-IV and to 91% or 96% in every histological
sub-type of OC. Moreover, in the present study we ob-
tained a better outcome for the diagnostic SE than that
attained by Skates et al. [33] and Zhang et al. [34] who
found that multiple-marker panels (M-CSF, CA72-4
(carbohydrate antigen 72–4) and CA 125 - 70%; M-CSF,
CA72-4, CA 125 and CA15-3 (carbohydrate antigen
15–3) - 71% respectively) significantly increased pre-
operative early-stage sensitivity. A comparable increase
in the diagnostic SE was previously observed, although it
regarded the combined analysis of VEGF with CA 125
and HE4 [59]. Similarly, NPV levels were improved to
74% - stage I, to 91–100% in stages II-IV and to 96% or
92% in the serous and endometrioid sub-types, substan-
tially higher than NPV levels provided by either marker
used alone. These observations are in opposition to the
results of other authors who observed distinctly higher
values of these diagnostic criteria for HE4 than for CA
125 in premenopausal subjects [60], or higher values of
NPV for HE4 or CA 125 alone (72% and 92%, respect-
ively) in a group of Asian women [61]. We were unable
to compare our findings regarding the aforementioned
panel of biomarkers with the findings of other authors,
since no reports on the subject are available. The results
of the current study support our previous findings re-
garding the usefulness of M-CSF and CA 125 in the
diagnostics of this malignancy [10].
The AUC numerically describes the overall perform-
ance of a marker, with the AUC of 1 indicating a perfect
SE and SP. We observed that M-CSF had the highest,
comparable to conventional markers, diagnostic power
in the groups with stages I-III of OC (0.7676, 0.8662,
0.9336, respectively) and in the patients with serous
sub-type of EOC (0.9058). We demonstrated that the
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vestigation consistently provided the highest sensitivity
for the detection of every stage, and particularly early
stages, of EOC with the AUC value of 0.9069–0.9894,
which was superior to the value of either marker used
alone. Furthermore, we observed that the areas under
the curve for the cytokine tested and the comparative
markers were statistically significantly larger compared
to AUC = 0,5 - borderline of diagnostic usefulness of the
test. Test data published by Zhang et al. [34] are at vari-
ance with our present results (AUC for: CA 125–0.908,
M-CSF - 0.792), although in a few previous studies the
AUC values of CA 125 and HE4 for differentiating
EOC were 0.82–0.95 and 0.85–0.96, respectively
[6,49,50,52,56,62] and were significantly higher when
the markers were used in combination [50], the results
similar to our findings.
Conclusions
In conclusion, challenges regarding the early diagnosis
of epithelial ovarian cancer remain. Although hundreds
of biomarkers have been identified as being associated
with this common type of cancer, their efficacy in the
early diagnosis of the disease has not yet been established.
To our knowledge, this is the first study in which plasma
levels of M-CSF, HE4 and CA 125 were simultaneously
analysed in a relatively large group of untreated patients
with primary malignant and nonmalignant ovarian tumors.
While each marker has its own strengths and weaknesses,
CA 125 still remains better than HE4 in the diagnostics of
EOC patients. However, M-CSF obtained even better re-
sults than CA 125. Our findings suggest a highly potential
role for M-CSF as a tumor marker in the diagnosis of the
serous sub-type of EOC, particularly in combination with
HE4 and CA 125 as a new diagnostic panel. The utilization
of the tested parameters in combination may also
measurably improve the OC diagnosis in the early
stages. Additional studies with larger, early-stage car-
cinoma patient groups may be needed to further
strengthen the statistical power of the evidence.
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